The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedEvolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative NeoplasmsA Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis.Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging ApproachesHow ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 MutationExperience with ruxolitinib in the treatment of polycythaemia vera.Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?JAK2 inhibitors for myeloproliferative neoplasms: what is next?Investigational Janus kinase inhibitors in development for myelofibrosis.Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?Ruxolitinib dose management as a key to long-term treatment success.Myelofibrosis: an update on drug therapy in 2016.Myeloproliferative neoplasm stem cells.The promise of Janus kinase inhibitors in the treatment of hematological malignancies.Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidenceAnalysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study.Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.Complete remission in a patient with JAK2- and IDH2-positive myelofibrosisProteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches.Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis.The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.Developmental Therapeutics in Myeloproliferative Neoplasms.SOHO State-of-the-Art Update and Next Questions: MPN.Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia.Mutations in myeloproliferative neoplasms - their significance and clinical use.Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.Novel Therapies for Myelofibrosis.Targeting a regulator of protein homeostasis in myeloproliferative neoplasms.Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations.Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment.Quantitative competitive allele-specific TaqMan duplex PCR (qCAST-Duplex PCR) assay: a refined method for highly sensitive and specific detection of V617F mutant allele burdens
P2860
Q26738514-D4C590C1-3C1C-40E2-ADA7-7B8C90ADA4E3Q26766319-49D50846-DEDE-420B-A5FF-9176A86C323CQ27342179-4858937F-9CDF-4795-BE08-7E5DF163ED90Q28076096-A2064683-3748-46E9-955A-3C38BA31C8B5Q30240043-8BB9902F-DC9B-4F68-B536-CC38882782E7Q30244032-203A954E-10B0-4F86-BD64-6FFC84BBCA08Q33435178-DCDA4C18-0D35-4EE0-AD57-6CA2F26F6DF9Q33439559-A93EF374-0E86-4C09-8AC1-C893AC625E25Q33443246-AE8C75CF-A131-4B07-AAC8-EF259B051CD3Q33605624-D6076430-AD3D-4A54-8221-ABF114945A93Q36308248-B8D765CC-A463-4DCA-ADC7-C4B96AC12D47Q36782943-FDB95911-96BE-42EB-9EE7-BB2BA151DCA3Q37679175-F870629C-BE45-4668-910B-844C333157DAQ38597994-C4FA7AE0-A391-4075-B1D1-FB04157635BCQ38684435-75A1E84C-E6A7-42AA-8335-7364254E335BQ38691019-9A47009C-145C-417E-BAC1-561BCE210F71Q38725723-B72504DB-E2FD-48CC-9994-2FFA5B527CEAQ38791273-8CE096CF-DBEE-4382-91AA-B359E84CC71BQ38938939-92FAC847-90D3-4CAE-82C7-E9326660DDDCQ38989215-3A1226B4-6E6D-45D7-AA9E-A11905506D67Q39118859-146768B1-0FB2-4A94-90DC-C303DD0E6776Q39170500-D2AC3580-3BE0-4E54-9E4A-10C946A1DBE2Q39554738-E2CF84B0-42D3-458A-AB60-411453E7A0F9Q40555261-56D6FD74-6D98-4A89-BA4F-235397BFAC00Q40742224-E87EC3FA-81A5-496C-842E-39325996EEE7Q42361243-616598D1-E26E-493A-97DD-147D9D04D2D0Q47102210-4C21C545-6BEC-4E6A-AC2C-3BC20F766B47Q47140652-0091BF1C-1E9B-487D-A3D7-E687C508733DQ47581193-3C79AB3D-BA2E-48D6-B81C-FD25D57BDDCCQ48008083-09E7D171-7F3E-4E13-9B48-C7DE5CA55E6EQ49580473-431AFCEE-6A39-4B21-85EE-07157264ED5BQ49887981-58CBBFAE-84C4-47EF-9E30-27375DD4E134Q50072000-A894BFAA-2106-4C43-AB9C-52FD29699FCFQ51048904-492ABE92-2DEC-4161-9310-9B33A2B6560EQ51354558-1EEDF741-982C-4422-997A-792EE44CA05BQ52817185-C541FCE3-D05A-46FE-8EB1-BD7A524A8035Q54223977-1D4216E8-557B-4CA7-8B04-8443BB76C9FAQ54977480-A008D9C6-FD12-4FF0-85AD-C51CAEC7891CQ55396890-166D867D-16A7-4799-B1E8-EA3A2985281CQ58793774-9D06AD3A-6CE0-492A-AFC6-1A3DB586EEB7
P2860
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The effect of long-term ruxoli ...... n patients with myelofibrosis.
@ast
The effect of long-term ruxoli ...... n patients with myelofibrosis.
@en
type
label
The effect of long-term ruxoli ...... n patients with myelofibrosis.
@ast
The effect of long-term ruxoli ...... n patients with myelofibrosis.
@en
prefLabel
The effect of long-term ruxoli ...... n patients with myelofibrosis.
@ast
The effect of long-term ruxoli ...... n patients with myelofibrosis.
@en
P2093
P2860
P1433
P1476
The effect of long-term ruxoli ...... n patients with myelofibrosis.
@en
P2093
Dilan Paranagama
Jerald Radich
Michael Deininger
Reid Huber
Timothy C Burn
P2860
P304
P356
10.1182/BLOOD-2015-03-635235
P407
P577
2015-07-30T00:00:00Z